ClinicalTrials.gg
CompletedNCT07319559Updated Jan 6, 2026

Clinical Trial to Evaluate the Safety, Pharmacokinetic Characteristics of DW5124 and DW5124-R, and the Effect of Food on DW5124 in Healthy Adult Volunteers

A Phase 1 interventional study of DW5124 and DW5124-R in Mixed Dyslipidemia, sponsored by Daewon Pharmaceutical Co., Ltd.. Completed at 1 site in South Korea. Open to participants aged 19 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-06.

Sponsored by Daewon Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled May 2025, registered Dec 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
19 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 155 studies in Dyslipidemias with a site in Korea, Republic of — 30 open to participants now, 39 under way, 5 of them phase 3. Dyslipidemias · Korea, Republic of.

Enrollment
89th of 124
55 · median 80
Started
2025
with 13 others
Phase 1
58 of 155
7 open now
Registered
142nd of 155
by date
Lead sponsor
5 of 155
Daewon Pharmaceutical Co., Ltd.

Among the 155 studies in Dyslipidemias with a site in Korea, Republic of, this one is the 89th largest by enrollment of the 124 interventional ones that give a count, is one of 14 that started in 2025, is one of 58 in phase 1, and was the 142nd registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

30 of the 155 studies in Dyslipidemias with a site in Korea, Republic of are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 19 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies in Dyslipidemias with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study aimed to evaluate the safety and pharmacokinetic characteristics of DW5124 and DW5124-R, and the effect of food on DW5124, in healthy adult volunteers.

03

Conditions studied

  • Mixed Dyslipidemia

Browse trials for

04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Volunteers who are ≥19 years and >65 years old
  • Body weight ≥50.0 kg and between 18.0 and 30.0 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Medical History
  • In the case of women, pregnant(Urine-HCG positive) or lactating women
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Sequence A

    cross-over

    Drug: DW5124 · Drug: DW5124-R

  • Experimental
    Sequence B

    cross-over

    Drug: DW5124 · Drug: DW5124-R

  • Experimental
    Sequence C

    cross-over

    Drug: DW5124 · Drug: DW5124-R

  • Experimental
    Sequence D

    cross-over

    Drug: DW5124 · Drug: DW5124-R

  • Experimental
    Sequence E

    cross-over

    Drug: DW5124 · Drug: DW5124-R

  • Experimental
    Sequence F

    cross-over

    Drug: DW5124 · Drug: DW5124-R

Interventions

  • DrugDW5124

    DW5124 on fasted or fed condition

  • DrugDW5124-R

    DW5124-R on fasted or fed condition

06

What researchers measure

Primary outcomes

  1. Peak Plasma Concentration (Cmax)

    Pharmacokinetics of DW5124-fed and DW5124-fasting, Pharmacokinetics of DW5124-fed and DW5124-R-fed

    Time frame: up to 72 hour

  2. Area under the plasma concentration versus time curve (AUC)

    Pharmacokinetics of DW5124-fed and DW5124-fasting, Pharmacokinetics of DW5124-fed and DW5124-R-fed

    Time frame: up to 72 hour

Secondary outcomes

  1. Time to maximum plasma concentration (Tmax)

    Pharmacokinetics of DW5124-fed, DW5124-fasting, DW5124-R-fed

    Time frame: up to 72 hour

  2. Terminal half life (t1/2)

    Pharmacokinetics of DW5124-fed, DW5124-fasting, DW5124-R-fed

    Time frame: up to 72 hour

  3. Apparent clearance (CL/F)

    Pharmacokinetics of DW5124-fed, DW5124-fasting, DW5124-R-fed

    Time frame: up to 72 hour

  4. Apparent volume of distribution (Vd/F)

    Pharmacokinetics of DW5124-fed, DW5124-fasting, DW5124-R-fed

    Time frame: up to 72 hour

07

Study locations

1 site
  • Chungbuk National University Hospital
    Cheongju-si, South Korea
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in May 2025, 0 months.

Of 77 industry-sponsored phase 1 interventional studies under Dyslipidemias, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 0 months is below that.

Counting every sponsor, half of 83 studies reached it within 2 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2025
First posted
Jan 6, 2026
StartActual
May 8, 2025
Primary completionActual
May 11, 2025
CompletionActual
Jun 5, 2025
Last update
Jan 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07319559
Responsible party
Sponsor
First posted
Jan 6, 2026
Start date
May 8, 2025
Primary completion
May 11, 2025
Completion
Jun 5, 2025
Last update
Jan 6, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion